Sparks commentary

Healthcare

Sparks

Isofol Medical (ST: ISOFOL) – first cohort complete in arfolitixorin study
Published by Arron Aatkar, PhD

Isofol Medical has announced completion of the first patient cohort in its ongoing Phase I/II trial of arfolitixorin in combination with standard 5-FU-based first-line therapy for metastatic colorectal cancer. The study aims to optimise dosing while assessing safety and pharmacokinetics, and exploring early signs of efficacy. This marks an important early milestone in re-establishing clinical momentum for arfolitixorin after prior setbacks. Following a meeting with the Safety Review Committee, the company has received recommendation to proceed to the next dose cohort.

Latest

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free